At a glance
ClinicalIndex Comparison RecordN/ACompleted· 2,662 enrolled
Drug / intervention
Remicadebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Crohn's Disease European Registry. A Prospective, Observational, Postmarketing Safety Surveillance Registry of Patients Treated With Remicade® or Standard Therapy
In Brief
An observational study evaluating Remicade for Crohn's Disease. Completed, enrolled 2,662 participants.
Detailed Summary
Prospective, observational, parallel-group, postmarketing safety surveillance registry in participants treated with Remicade or standard therapy for active or fistulizing Crohn's disease (CD). The follow-up period is up to 5 years. The participants in the standard therapy group may switch over to Remicade any time during the follow-up period
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCrohn's Disease
Countries--
Collaborators--
Timeline
N/ACompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2003
First PostedJun 2008
Primary CompletionFeb 2013
TodayJul 2026
First PostedJun 26, 2008
Enrollment StartJul 1, 2003
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 9.6 yearsPosted 18.0 years ago
Interventions
Remicadebiological
The treating physician will determine the treatment regimen and dose of Remicade.